Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Singapore"

142 News Found

Gland Pharma appoints Shyamakant Giri as CEO
People | October 19, 2024

Gland Pharma appoints Shyamakant Giri as CEO

Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals


DKSH partners with R-Biomeds to bring oncology and thyroid treatments to Cambodia
Supply Chain | October 09, 2024

DKSH partners with R-Biomeds to bring oncology and thyroid treatments to Cambodia

DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia


Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories
News | October 06, 2024

Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories

The acquisition will strengthen the overall company’s position as leading global CRO services partner


Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility
News | October 04, 2024

Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility

US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years


Morepen Laboratories appoints Amrit Ravi as Vice President
People | October 01, 2024

Morepen Laboratories appoints Amrit Ravi as Vice President

He holds a Master’s in Management from the National University of Singapore


USFDA inspection update on Jubilant HollisterStier’s Montreal facility
Drug Approval | September 30, 2024

USFDA inspection update on Jubilant HollisterStier’s Montreal facility

HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures


Biocon Biologics Global to raise funds through senior secured notes
News | September 26, 2024

Biocon Biologics Global to raise funds through senior secured notes

The Notes shall not be offered or sold in India


Strides receives USFDA approval for Fluoxetine Tabs 60 mg
Drug Approval | September 16, 2024

Strides receives USFDA approval for Fluoxetine Tabs 60 mg

Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules


USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington
Drug Approval | September 11, 2024

USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington

Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding


Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg
Drug Approval | September 06, 2024

Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug